AstraZeneca PLC banner

AstraZeneca PLC
BMV:AZNN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
BMV:AZNN
Watchlist
Price: 1 628 MXN 1.25% Market Closed
Market Cap: Mex$5T

Relative Value

The Relative Value of one AZNN stock under the Base Case scenario is 2 264.09 MXN. Compared to the current market price of 1 628 MXN, AstraZeneca PLC is Undervalued by 28%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZNN Relative Value
Base Case
2 264.09 MXN
Undervaluation 28%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

AZNN Competitors Multiples
AstraZeneca PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
AstraZeneca PLC
BMV:AZNN
216.4B MXN 4.9 28.3 15.7 22.2
US
Eli Lilly and Co
NYSE:LLY
856.7B USD 13.1 41.5 28 29.9
US
Johnson & Johnson
NYSE:JNJ
566.8B USD 6 21.1 14.7 18.1
CH
Roche Holding AG
SIX:ROG
243.3B CHF 4 18.9 11.2 12.6
US
Merck & Co Inc
NYSE:MRK
282.6B USD 4.3 15.5 9.6 11.7
CH
Novartis AG
SIX:NOVN
222.2B CHF 5.1 20.5 12.7 16.3
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.7 9
US
Pfizer Inc
NYSE:PFE
153.4B USD 2.5 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
115.7B USD 2.4 16.4 7 8.6
FR
Sanofi SA
PAR:SAN
93.7B EUR 2 12 10.1 10.1
P/E Multiple
Earnings Growth PEG
UK
AstraZeneca PLC
BMV:AZNN
Average P/E: 20.4
28.3
26%
1.1
US
Eli Lilly and Co
NYSE:LLY
41.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.1
7%
3
CH
Roche Holding AG
SIX:ROG
18.9
14%
1.3
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1
FR
Sanofi SA
PAR:SAN
12
16%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
AstraZeneca PLC
BMV:AZNN
Average EV/EBITDA: 45.4
15.7
13%
1.2
US
Eli Lilly and Co
NYSE:LLY
28
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.4
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.6
3%
3.2
CH
Novartis AG
SIX:NOVN
12.7
5%
2.5
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
1%
7.7
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7
-10%
N/A
FR
Sanofi SA
PAR:SAN
10.1
19%
0.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
AstraZeneca PLC
BMV:AZNN
Average EV/EBIT: 99.1
22.2
21%
1.1
US
Eli Lilly and Co
NYSE:LLY
29.9
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.1
6%
3
CH
Roche Holding AG
SIX:ROG
12.6
6%
2.1
US
Merck & Co Inc
NYSE:MRK
11.7
6%
2
CH
Novartis AG
SIX:NOVN
16.3
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.6
-7%
N/A
FR
Sanofi SA
PAR:SAN
10.1
12%
0.8
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett